Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-08

AUTHORS

T. Ichikura, S. Tomimatsu, Y. Okusa, T. Yahara, K. Uefuji, S. Tamakuma

ABSTRACT

Purpose: 5-Fluorouracil (5-FU) remains a standard therapy for patients with advanced gastric cancer. There has been no study using an oral regimen with a combination of tegafur, a masked compound of 5-FU, and leucovorin in gastric cancer. The purpose of this study was to determine whether orally administered low-dose leucovorin enhances thymidylate synthase (TS) inhibition when added to tegafur-uracil (UFT) in patients with gastric cancer. Methods: A group of 26 patients with resectable gastric cancer were assigned to one of two regimens: UFT alone or UFT plus leucovorin. UFT, equivalent to 400 mg/day tegafur, with or without 30 mg/day leucovorin, was administered orally in divided daily doses every 12 h for 3 consecutive days prior to surgery. Tumor specimens were taken immediately following gastrectomy, and the TS inhibition rate (TSIR) was determined using a ligand-binding assay. Results: The TSIR was significantly higher in the UFT plus leucovorin group than in the UFT alone group (P<0.01). The TSIR in the patients treated with UFT alone ranged between 14% and 50%, while six of the eight patients treated with UFT plus leucovorin had a TSIR of 55% or higher. The remaining two patients in the group treated with UFT plus leucovorin, with a TSIR of 31% and 44%, had undifferentiated tumors. Conclusion: Our results suggest that orally administered low-dose leucovorin can add to the efficacy of UFT in patients with gastric cancer, and provide preliminary data for a randomized clinical trial. More... »

PAGES

401-405

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002800050503

DOI

http://dx.doi.org/10.1007/s002800050503

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025783877

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/8765432


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leucovorin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stomach Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tegafur", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thymidylate Synthase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uracil", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ichikura", 
        "givenName": "T.", 
        "id": "sg:person.0634231701.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634231701.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomimatsu", 
        "givenName": "S.", 
        "id": "sg:person.01122224456.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122224456.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okusa", 
        "givenName": "Y.", 
        "id": "sg:person.01277575426.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277575426.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yahara", 
        "givenName": "T.", 
        "id": "sg:person.01345710626.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345710626.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uefuji", 
        "givenName": "K.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tamakuma", 
        "givenName": "S.", 
        "type": "Person"
      }
    ], 
    "datePublished": "1996-08", 
    "datePublishedReg": "1996-08-01", 
    "description": "Abstract\u2002Purpose: 5-Fluorouracil (5-FU) remains a standard therapy for patients with advanced gastric cancer. There has been no study using an oral regimen with a combination of tegafur, a masked compound of 5-FU, and leucovorin in gastric cancer. The purpose of this study was to determine whether orally administered low-dose leucovorin enhances thymidylate synthase (TS) inhibition when added to tegafur-uracil (UFT) in patients with gastric cancer. Methods: A group of 26 patients with resectable gastric cancer were assigned to one of two regimens: UFT alone or UFT plus leucovorin. UFT, equivalent to 400\u2005mg/day tegafur, with or without 30\u2005mg/day leucovorin, was administered orally in divided daily doses every 12\u2005h for 3 consecutive days prior to surgery. Tumor specimens were taken immediately following gastrectomy, and the TS inhibition rate (TSIR) was determined using a ligand-binding assay. Results: The TSIR was significantly higher in the UFT plus leucovorin group than in the UFT alone group (P<0.01). The TSIR in the patients treated with UFT alone ranged between 14% and 50%, while six of the eight patients treated with UFT plus leucovorin had a TSIR of 55% or higher. The remaining two patients in the group treated with UFT plus leucovorin, with a TSIR of 31% and 44%, had undifferentiated tumors. Conclusion: Our results suggest that orally administered low-dose leucovorin can add to the efficacy of UFT in patients with gastric cancer, and provide preliminary data for a randomized clinical trial.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s002800050503", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "keywords": [
      "TS inhibition rate", 
      "low-dose leucovorin", 
      "gastric cancer", 
      "oral regimen", 
      "synthase inhibition", 
      "combination of tegafur", 
      "efficacy of UFT", 
      "resectable gastric cancer", 
      "advanced gastric cancer", 
      "randomized clinical trials", 
      "day leucovorin", 
      "leucovorin group", 
      "standard therapy", 
      "alone group", 
      "daily doses", 
      "clinical trials", 
      "masked compound", 
      "leucovorin", 
      "UFT", 
      "tumor specimens", 
      "patients", 
      "consecutive days", 
      "cancer", 
      "ligand-binding assays", 
      "regimen", 
      "preliminary data", 
      "tegafur", 
      "inhibition rate", 
      "group", 
      "inhibition", 
      "gastrectomy", 
      "regimens", 
      "surgery", 
      "therapy", 
      "tumors", 
      "doses", 
      "trials", 
      "efficacy", 
      "study", 
      "days", 
      "assays", 
      "purpose", 
      "specimens", 
      "rate", 
      "enhances", 
      "combination", 
      "data", 
      "results", 
      "compounds", 
      "low-dose leucovorin enhances", 
      "leucovorin enhances", 
      "day tegafur", 
      "UFT alone group"
    ], 
    "name": "Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer", 
    "pagination": "401-405", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025783877"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002800050503"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "8765432"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002800050503", 
      "https://app.dimensions.ai/details/publication/pub.1025783877"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_289.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s002800050503"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002800050503'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002800050503'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002800050503'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002800050503'


 

This table displays all metadata directly associated to this object as RDF triples.

212 TRIPLES      21 PREDICATES      96 URIs      87 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002800050503 schema:about N04aecc040e5f45f993b9d14d1b018529
2 N104a8bc2c11049c595575e0bda875b64
3 N61572e8bc2e34e55ab1785475d7b7f83
4 N6914d2b712c74c6c8b7fcbb90ee125e0
5 N736c1c59e8724e5abf40d06b41ac3fa8
6 N751b9bf036904a858e7b809edd3121a7
7 N92771326e6c847df8034083a4d309931
8 N9adc4c9dbd6e4f6189a07777046e8ed7
9 Nc52976f32019438c9d182be3de072555
10 Nc8ed513419364d91842ed1099a124f26
11 Ncb0b85fad65c44a091ee6de491f35f67
12 Ne550bb603c3847908c129e942669814f
13 Nfb11e93570ec4d558806a50ed8a0acaa
14 Nfbcc4d46ae6449b586989736a3cf6b95
15 Nffb9d51da93046d5815c17a43723f5c2
16 anzsrc-for:11
17 anzsrc-for:1103
18 anzsrc-for:1112
19 schema:author N5101024adad848cea9df166f3fcf6922
20 schema:datePublished 1996-08
21 schema:datePublishedReg 1996-08-01
22 schema:description Abstract Purpose: 5-Fluorouracil (5-FU) remains a standard therapy for patients with advanced gastric cancer. There has been no study using an oral regimen with a combination of tegafur, a masked compound of 5-FU, and leucovorin in gastric cancer. The purpose of this study was to determine whether orally administered low-dose leucovorin enhances thymidylate synthase (TS) inhibition when added to tegafur-uracil (UFT) in patients with gastric cancer. Methods: A group of 26 patients with resectable gastric cancer were assigned to one of two regimens: UFT alone or UFT plus leucovorin. UFT, equivalent to 400 mg/day tegafur, with or without 30 mg/day leucovorin, was administered orally in divided daily doses every 12 h for 3 consecutive days prior to surgery. Tumor specimens were taken immediately following gastrectomy, and the TS inhibition rate (TSIR) was determined using a ligand-binding assay. Results: The TSIR was significantly higher in the UFT plus leucovorin group than in the UFT alone group (P<0.01). The TSIR in the patients treated with UFT alone ranged between 14% and 50%, while six of the eight patients treated with UFT plus leucovorin had a TSIR of 55% or higher. The remaining two patients in the group treated with UFT plus leucovorin, with a TSIR of 31% and 44%, had undifferentiated tumors. Conclusion: Our results suggest that orally administered low-dose leucovorin can add to the efficacy of UFT in patients with gastric cancer, and provide preliminary data for a randomized clinical trial.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf N0b715211ce8c45b682d9d0aad5d7fad8
27 N1c4919d97f9046deb42e7506aff254ed
28 sg:journal.1088364
29 schema:keywords TS inhibition rate
30 UFT
31 UFT alone group
32 advanced gastric cancer
33 alone group
34 assays
35 cancer
36 clinical trials
37 combination
38 combination of tegafur
39 compounds
40 consecutive days
41 daily doses
42 data
43 day leucovorin
44 day tegafur
45 days
46 doses
47 efficacy
48 efficacy of UFT
49 enhances
50 gastrectomy
51 gastric cancer
52 group
53 inhibition
54 inhibition rate
55 leucovorin
56 leucovorin enhances
57 leucovorin group
58 ligand-binding assays
59 low-dose leucovorin
60 low-dose leucovorin enhances
61 masked compound
62 oral regimen
63 patients
64 preliminary data
65 purpose
66 randomized clinical trials
67 rate
68 regimen
69 regimens
70 resectable gastric cancer
71 results
72 specimens
73 standard therapy
74 study
75 surgery
76 synthase inhibition
77 tegafur
78 therapy
79 trials
80 tumor specimens
81 tumors
82 schema:name Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer
83 schema:pagination 401-405
84 schema:productId N2b9f52b039314a3aa5f476956f3e1c48
85 N59959f53bb244dad9c63f7e145a71610
86 N97626fd2b04f4efaaf7ba8389c8b4c9f
87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025783877
88 https://doi.org/10.1007/s002800050503
89 schema:sdDatePublished 2022-01-01T18:08
90 schema:sdLicense https://scigraph.springernature.com/explorer/license/
91 schema:sdPublisher N796406025d33488ab507712a1f241976
92 schema:url https://doi.org/10.1007/s002800050503
93 sgo:license sg:explorer/license/
94 sgo:sdDataset articles
95 rdf:type schema:ScholarlyArticle
96 N04aecc040e5f45f993b9d14d1b018529 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Aged
98 rdf:type schema:DefinedTerm
99 N0b715211ce8c45b682d9d0aad5d7fad8 schema:volumeNumber 38
100 rdf:type schema:PublicationVolume
101 N104a8bc2c11049c595575e0bda875b64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Prospective Studies
103 rdf:type schema:DefinedTerm
104 N15d270a4c7e24adb83d99f01ad7fb1f1 rdf:first sg:person.01277575426.07
105 rdf:rest N1e031b13d9fb4f70b1a75d76cee316a6
106 N1c4919d97f9046deb42e7506aff254ed schema:issueNumber 5
107 rdf:type schema:PublicationIssue
108 N1e031b13d9fb4f70b1a75d76cee316a6 rdf:first sg:person.01345710626.62
109 rdf:rest N76bd622b39174c9483de8f03b4c4a0bf
110 N2b9f52b039314a3aa5f476956f3e1c48 schema:name dimensions_id
111 schema:value pub.1025783877
112 rdf:type schema:PropertyValue
113 N5101024adad848cea9df166f3fcf6922 rdf:first sg:person.0634231701.10
114 rdf:rest Nca658a66d1294178975004c8342db3c3
115 N51f209661325475b9d1a6dbab8ebd01b schema:affiliation grid-institutes:grid.416614.0
116 schema:familyName Tamakuma
117 schema:givenName S.
118 rdf:type schema:Person
119 N59959f53bb244dad9c63f7e145a71610 schema:name doi
120 schema:value 10.1007/s002800050503
121 rdf:type schema:PropertyValue
122 N61572e8bc2e34e55ab1785475d7b7f83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Uracil
124 rdf:type schema:DefinedTerm
125 N6914d2b712c74c6c8b7fcbb90ee125e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Thymidylate Synthase
127 rdf:type schema:DefinedTerm
128 N736c1c59e8724e5abf40d06b41ac3fa8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Antimetabolites, Antineoplastic
130 rdf:type schema:DefinedTerm
131 N751b9bf036904a858e7b809edd3121a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Tegafur
133 rdf:type schema:DefinedTerm
134 N76bd622b39174c9483de8f03b4c4a0bf rdf:first Nf8f5ad35a32545679d1da9deb3dde478
135 rdf:rest N799431b2efca4426887c965c9781ba29
136 N796406025d33488ab507712a1f241976 schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 N799431b2efca4426887c965c9781ba29 rdf:first N51f209661325475b9d1a6dbab8ebd01b
139 rdf:rest rdf:nil
140 N92771326e6c847df8034083a4d309931 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Antineoplastic Combined Chemotherapy Protocols
142 rdf:type schema:DefinedTerm
143 N97626fd2b04f4efaaf7ba8389c8b4c9f schema:name pubmed_id
144 schema:value 8765432
145 rdf:type schema:PropertyValue
146 N9adc4c9dbd6e4f6189a07777046e8ed7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Humans
148 rdf:type schema:DefinedTerm
149 Nc52976f32019438c9d182be3de072555 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Male
151 rdf:type schema:DefinedTerm
152 Nc8ed513419364d91842ed1099a124f26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Neoplasm Staging
154 rdf:type schema:DefinedTerm
155 Nca658a66d1294178975004c8342db3c3 rdf:first sg:person.01122224456.77
156 rdf:rest N15d270a4c7e24adb83d99f01ad7fb1f1
157 Ncb0b85fad65c44a091ee6de491f35f67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Drug Combinations
159 rdf:type schema:DefinedTerm
160 Ne550bb603c3847908c129e942669814f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Female
162 rdf:type schema:DefinedTerm
163 Nf8f5ad35a32545679d1da9deb3dde478 schema:affiliation grid-institutes:grid.416614.0
164 schema:familyName Uefuji
165 schema:givenName K.
166 rdf:type schema:Person
167 Nfb11e93570ec4d558806a50ed8a0acaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Administration, Oral
169 rdf:type schema:DefinedTerm
170 Nfbcc4d46ae6449b586989736a3cf6b95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Stomach Neoplasms
172 rdf:type schema:DefinedTerm
173 Nffb9d51da93046d5815c17a43723f5c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Leucovorin
175 rdf:type schema:DefinedTerm
176 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
177 schema:name Medical and Health Sciences
178 rdf:type schema:DefinedTerm
179 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
180 schema:name Clinical Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
183 schema:name Oncology and Carcinogenesis
184 rdf:type schema:DefinedTerm
185 sg:journal.1088364 schema:issn 0344-5704
186 1432-0843
187 schema:name Cancer Chemotherapy and Pharmacology
188 schema:publisher Springer Nature
189 rdf:type schema:Periodical
190 sg:person.01122224456.77 schema:affiliation grid-institutes:grid.416614.0
191 schema:familyName Tomimatsu
192 schema:givenName S.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122224456.77
194 rdf:type schema:Person
195 sg:person.01277575426.07 schema:affiliation grid-institutes:grid.416614.0
196 schema:familyName Okusa
197 schema:givenName Y.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277575426.07
199 rdf:type schema:Person
200 sg:person.01345710626.62 schema:affiliation grid-institutes:grid.416614.0
201 schema:familyName Yahara
202 schema:givenName T.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345710626.62
204 rdf:type schema:Person
205 sg:person.0634231701.10 schema:affiliation grid-institutes:grid.416614.0
206 schema:familyName Ichikura
207 schema:givenName T.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634231701.10
209 rdf:type schema:Person
210 grid-institutes:grid.416614.0 schema:alternateName First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP
211 schema:name First Department of Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Japan Tel. 0429-95-1511, ext. 2356; Fax 0429-95-0638, JP
212 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...